

1 June 2006

**CSL LIMITED**

**CSL APPOINTS NEW DIRECTOR**

CSL today announced that Professor John Shine has been appointed a Director of the Company and will join the CSL Board effective immediately.

Professor John Shine is Executive Director of the Garvan Institute of Medical Research, Professor of Medicine and Professor of Molecular Biology at the University of NSW, Chairman of the National Health and Medical Research Council and a Vice-President of the Australian Academy of Science.

CSL's Chairman, Mr Peter Wade, said that he was delighted that Professor Shine had accepted the appointment to the Board and how much he was looking forward to working with Professor Shine, whose broad research experience in the field of medicine and molecular biology will be of great potential benefit for CSL as the company increases its investment in innovative research and development in these fields.

**About CSL Limited**

Headquartered in Melbourne, CSL Limited (ASX: CSL) is a global, specialty biopharmaceutical company that develops, manufactures and markets products to treat and prevent serious human medical conditions.

For further information, please contact:

**Media Contacts:**

Dr Rachel David  
Director of Public Affairs  
Phone: 0401 775 779  
Email: [rachel.david@csl.com.au](mailto:rachel.david@csl.com.au)

**Investor Contact:**

Mark Dehring  
Director of Investor Relations  
Phone: 61 3 9389 2818  
Email: [mark.dehring@csl.com.au](mailto:mark.dehring@csl.com.au)